Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05754957 · ClinicalTrials.gov registry record · Phase 3
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
A Phase 3 study of Acute Coronary Syndrome, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 14,194
- Enrollment target
- 20
- Study locations
NCT05754957: Active Phase 3 study of Acute Coronary Syndrome, sponsored by Janssen Research & Development.
NCT05754957 is a Phase 3 study of Acute Coronary Syndrome that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 14,194 participants, above the 2,367-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (500% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05754957, a Phase 3 study of Acute Coronary Syndrome, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 14,194 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Primary Outcome
Time to first occurrence of any component of MACE will be reported. MACE is a composite of cardiovascular (CV) death, myocardial infarction (MI), and ischemic stroke.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Milvexian
Study Locations (20)
California
- Bakersfield Memorial Hospital - Bakersfield
- Mission Cardiovascular Research Institute - Fremont
- Radin Cardiovascular Medical Group - Newport Beach
- Valley Clinical Trials, Inc. - Northridge
- Stanford University School of Medicine - Palo Alto
- VA Palo Alto Healthcare System - Palo Alto
- Huntington Hospital - Pasadena
- The Cardiovascular Center - Redding
- University Of California San Diego - San Diego
- San Diego Cardiac Center - San Diego
- VA San Diego Health Care System - San Diego
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- SORRA Research - Birmingham
- Ascension St. Vincent's Health System - Birmingham
- IMC-Diagnostic and Medical Clinic - Mobile
- Cardiology Associates of Mobile Inc - Mobile
Arizona
- Mercy Gilbert Medical Center - Gilbert
- Valleywise Health Medical Center - Phoenix
- HonorHealth Neurology - Scottsdale
Arkansas
- Arkansas Heart Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,194 participants |
| Start Date | 2023-04-07 |
| Est. Completion | 2026-10-19 |
| Phase | Phase 3 |
What the registry record for NCT05754957 still lists
NCT05754957 is an interventional study that assigns participants to a tested intervention. Its 14,194 participants enrollment target places it among the larger protocols in the corpus, above the 2,367-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (500% higher).
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05754957 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05754957 about?
NCT05754957 is a clinical study titled "A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome". The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
What is the current status of trial NCT05754957?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 14,194 participants. The study started on 2023-04-07. Estimated completion is 2026-10-19.
What conditions does trial NCT05754957 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT05754957?
The interventions under investigation include: Placebo (OTHER), Milvexian (DRUG).
Who is sponsoring clinical trial NCT05754957?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05754957 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05754957's enrollment target sits among peer trials
14,194 4th of 40 higher than 37 of 40 other Acute Coronary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
COMPLETED · Phase 3
-
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
COMPLETED · Phase 3
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI